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Background: To evaluate the prognostic value of axillary lymph node ratio (LNR) as compared to the number of
involved nodes (pN stage) in patients with axillary lymph node-positive breast cancer treated with mastectomy
without radiation.
Methods: We performed a retrospective analysis of the clinical data of patients with stage II-III node-positive breast
cancer (N=1068) between 1998 and 2007. Locoregional recurrence-free survival (LRFS) and overall survival (OS) were
compared based on the LNR and pN staging.
Results: A total of 780 cases were classified as pN1, 183 as pN2, and 105 as pN3. With respect to LNR, 690 cases
had a LNR from 0.01-0.20, 269 cases a LNR from 0.21-0.65, and 109 cases a LNR > 0.65. The median follow-up time
was 62 months. Univariate analysis showed that both LNR and pN stage were prognostic factors of LRFS and OS
(p<0.05). Multivariate analysis indicated that LNR was an independent prognostic factor of LRFS and OS (p<0.05).
pN stage had no significant effect on LRFS or OS (p>0.05). In subgroup analysis, the LNR identified groups of
patients with different survival rates based on pN stage.
Conclusions: LNR is superior to pN staging as a prognostic factor in lymph node-positive breast cancer after
mastectomy, and should be used as one of the indications for adjuvant radiation therapy.
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Studies have shown that radiation therapy improves
locoregional control of axillary lymph node-positive breast
cancer, and thereby benefits survival [1-3]. The positive
lymph node status has been used as an indicator for
adjuvant radiotherapy after mastectomy [4,5]. However,
overall outcomes can be variable depending on the extent
of axillary lymph node removal. Additionally, the decision
to perform radiation therapy is in part physician dependent.* Correspondence: hezhy@sysucc.org.cn
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reproduction in any medium, provided the orThe lymph node ratio (LNR) is defined as the ratio of
the number of positive axillary lymph nodes to the number
of removed axillary lymph nodes, and has attracted a great
deal of attention. Veronesi et al. [6] has suggested that use
of the LNR may minimize the difference between clinical
judgment and the real status of the lymph nodes that arises
due to differing physician practices. Currently, studies on
the LNR have been mainly focused on patients with 1–3
positive nodes [7,8]. The reliability of the LNR in
predicting the prognosis in patients with greater than 3
positive nodes has rarely been addressed. In this
retrospectively study, we compared the prognostic values
of the LNR and number of involved nodes (pN) staging in
1068 patients with axillary lymph node-positive breast
cancer without radiation therapy after mastectomy to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patients characteristics and univariate analysis of prognostic factors for survival
Characteristic LRFS OS
n 5-year (%) 10-year (%) p 5-year (%) 10-year (%) p
Age (y)
≤ 35 134 76.0 70.4 0.020* 74.4 66.4 0.113
> 35 934 85.4 82.7 80.5 67.4
Menopausal status
Premenopausal 697 81.8 79.3 0.026* 80.3 68.9 0.589
Postmenopausal 371 89.0 85.1 78.7 63.4
Tumor size
T1-2 916 86.4 83.6 <0.001* 81.8 70.9 <0.001*
T3-4 97 70.2 70.2 61.2 36.1
Unknown 55
No of positive lymph nodes
pN1 (1–3) 780 88.7 86.1 <0.001* 86.1 77.7 <0.001*
pN2 (4–9) 183 77.0 73.0 69.7 51.0
pN3 (≥ 10) 105 60.6 53.8 49.9 20.8
Lymph node ratio
< 0.20 690 90.2 87.7 <0.001* 87.1 78.6 <0.001*
0.21-0.65 269 78.6 74.9 75.1 60.9
> 0.65 109 57.5 52.3 44.3 21.5
ER status
Positive 599 85.9 84.4 0.008* 83.9 69.0 <0.001*
Negative 393 81.0 76.7 72.2 64.2
Unknown 76
PR status
Positive 652 85.9 83.4 0.008* 83.0 72.6 <0.001*
Negative 340 80.3 77.6 72.3 57.0
Unknown 76
HER-2-neu status
Positive 321 81.8 79.7 0.077 75.6 66.2 0.026*
Negative 585 85.5 82.0 82.7 71.2
Unknown 162
Chemotherapy regimen
CMF 142 82.1 79.6 0.332 76.0 60.1 0.069
Anthracycline and/or taxane 850 84.9 81.9 81.5 71.0
None/unknown 76
Hormone therapy
Yes 718 85.7 82.5 0.032* 83.7 70.5 <0.001*
None 350 81.4 78.8 71.2 60.4
LRFS, Locoregional recurrence-free survival; OS, Overall survival; ER, Estrogen receptor; PR, Progesterone receptor; Her-2, Human epithelial growth factor receptor
family 2; CMF, Cyclophosphamide, methotrexate, and 5-fluorouracil.
*p<0.05 indicates a significant difference.
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adjuvant radiation therapy in these patients.
Materials and methods
Study population
The study was performed in accordance with the Declar-
ation of Helsinki and was approved by the ethics commit-
tee of Sun Yat-Sen University Cancer Center. Written
consent was given by the patients for their information to
be stored in the hospital database and used for research. A
total of 1068 female stage II-III breast cancer patients
treated between January 1998 and May 2007 at the Sun
Yat-sen University Cancer Center were included in this
study. All patients were diagnosed with unilateral breast
cancer without initial distant metastasis, and underwent
mastectomy and axillary lymph node dissection. Staging
was based on the 2009 7th edition of the American Joint
Committee on Cancer (AJCC) staging system, and pa-
tients with a post-mastectomy pathological stage of T1-
4N1-3M0 were included. In all cases, the tumor was
completely dissected and surgical margins were negative.Figure 1 Kaplan-Meier cumulative survival curves for different lymph
survival and (C, D) overall survival for (A, C) pN and (B, D) LNR.No neo-adjuvant therapy was administered before surgery,
and no adjuvant radiotherapy was provided after surgery.
No patients had any serious comorbid conditions.
Clinical and pathological factors and lymph node status
Clinical and pathological characteristics were used to
assess the risk of locoregional recurrence and death,
and included age, menopausal status, T stage, pN
stage, and estrogen receptor (ER), progesterone receptor
(PR), and human epithelial growth factor receptor family
2 (Her-2) status. T staging and pN staging were
determined according to the AJCC staging system
(7th edition, 2009). LNR classifications were based
on the report by Vinh-Hung et al. [9]. Patients were
classified into 3 groups: LNR 0.01-0.20, LNR 0.21 - 0.65,
and LNR > 0.65.
Follow-up and survival endpoints
Follow-up was scheduled every 3–6 months after
surgery. Locoregional recurrence-free survival (LRFS)
and overall survival (OS) were the primary study endpoints.node ratio (LNR) and pN stage. (A, B) Locoregional recurrence-free
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firmed relapse on the chest wall, supra- and infraclavicular
fossa, axillary area, or internal mammary region. Mortality
was defined as breast cancer-related death.
Statistical analysis
Data were analyzed using SPSS 16.0 software. Kaplan-
Meier curves were generated to compare the survival rates.
The statistical significance of data was analyzed by log-rank
test. Cox stepwise regression analysis was used for
multivariate analysis, and significant variables in univariate
analysis as indicated by p<0.05 were included in the Cox
model. Statistical significance was set at p<0.05.
Results
Clinical and pathological factors and treatment protocol
A total of 1068 patients with a median age of 47 years
(range, 23–90 years) were included in the study. The
clinical and pathological characteristics of the patients
are summarized in Table 1. The median numbers of




≤ 35 vs. > 35 1.664 (1.082-2.558)
Menopausal status
Pre- vs. postmenopausal 1.623 (1.106-2.383)
Tumor size
T3-4 vs. T1-2 1.636 (1.029-2.600)
ER status
Negative vs. positive 1.536 (1.095-2.155)
PR status
Negative vs. positive 1.626 (1.148-2.302)
HER-2-neu status
Positive vs. negative —
Hormone therapy
None vs. yes 1.180 (0.731-1.904)
Lymph node ratio
< 0.20 1 (Reference)
0.21-0.65 1.886 (1.273-2.794)
> 0.65 5.013 (3.191-7.877)




LRFS, Locoregional recurrence-free survival; OS, Overall survival; ER, Estrogen recept
family 2; HR, Hazard ratio; CI, Confidence interval.
*p<0.05 indicates a significant difference.were 15 (1–45) and 2 (1–44), respectively. Based on the
pN staging system, 780 cases (73.1%) were classified as
N1, 183 cases (17.1%) as N2, and 105 cases (9.8%) as
N3. The median LNR was 0.14 (0.03-1.00). There were
690 cases (64.6%) with a LNR from 0.01-0.20, 269
(25.2%) with a LNR from 0.21-0.65, and 109 (10.2%)
with a LNR > 0.65. A total of 1032 patients (96.6%) re-
ceived chemotherapy following surgery. Among them,
142 cases underwent a regimen consisting of cyclo-
phosphamide, methotrexate, and 5-fluorouracil (CMF),
and 890 cases received regimens with anthracycline
and/or taxane. The other 36 patients did not receive
any chemotherapy. All patients with a positive
hormone receptor status were treated with endocrine
therapy using tamoxifen and aromatase inhibitors
after chemotherapy. Herceptin was used for 4 patients
with Her-2 overexpression.
Survival and disease progression
The median follow-up time for all patients was 62 months
(5–154 months). Locoregional recurrence occurred in 155and pN stage
OS
p HR (95% CI) p
0.020* —
0.105 —
0.037 1.392 (0.917-2.113) 0.121
0.013* 1.054 (0.699-1.590) 0.802




0.002* 1.964 (1.387-2.782) <0.001*
<0.001* 7.381 (5.161-10.557) <0.001*
0.522 1.327 (0.808-2.179) 0.263
0.907 1.654 (0.904-3.027) 0.103
or; PR, Progesterone receptor; Her-2, Human epithelial growth factor receptor
















< 0.20 667 90.3 88.2 0.002* 87.3 79.0 0.054
0.21-0.65 107 80.0 74.8 80.1 71.0





< 0.20 16 80.0 — <0.001* 84.4 56.3 0.004*
0.21-0.65 141 82.1 77.2 72.0 55.2





< 0.20 7 66.7 — 0.508 80.0 — 0.013*
0.21-0.65 21 59.2 — 69.3 —
> 0.65 77 62.2 49.8 41.4 15.4
LRFS, Locoregional recurrence-free survival; OS, Overall survival.
*p<0.05 indicates a significant difference.
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81.3%, respectively. The median time to recurrence was 23
months (range, 4–91 months). Supraclavicular fossa recur-
rence occurred in 73 cases (47.1%), chest wall recurrence in
47 cases (30.3%), axillary lymph node recurrence in 3
cases (1.9%), internal mammary recurrence in 2 cases
(1.3%), and infraclavicular fossa recurrence in 2 cases
(1.3%). There were 28 cases in which recurrence occurred
at ≥ 2 sites (18.1%). A total of 240 patients died, among
whom 229 died as a result of breast cancer and 11 died of
other disorders. The 5- and 10-year OS rates were 79.7%
and 67.3%, respectively.
Analysis of prognostic factors
Univariate analysis showed that age, menopausal
status, T stage, pN stage, LNR, ER and PR status, and
hormone therapy were all prognostic factors of LRFS
(p<0.05 ). The 10-year LRFS rates were 86.1%, 73.0%,
and 53.8% for stage pN1, pN2, and pN3, respectively
(p<0.001), while the rates were 87.7%, 74.9%, and
52.3% for a LNR of 0.01-0.20, LNR of 0.21 - 0.65,
and a LNR > 0.65, respectively (p<0.001). T stage, pN
stage, LNR, ER, PR, and Her-2 status, and hormone
therapy were all prognostic factors of OS (p< 0.0 5)
(Table 1 and Figure 1).
The variables demonstrating statistical significance by
univariate analysis were further analyzed using multivariate
analysis in the Cox regression model. When pN and
LNR were included as covariants, the LNR remained
an independent prognostic factor for LRFS and OS
(p<0.05), with a higher LNR indicating a higher risk,
but pN stage exhibited no effect on LRFS and OS
(p>0.0 5) (Table 2).
Prognostic significance of LNR based on pN stage
The subgroup analysis of the prognostic significance of
LNR according to different pN stages is shown in Table 3
and Figure 2. For pN1 patients, the 5-year and 10-year
LRFS for a LNR of 0.21-0.65 were 80.4% and 74.8%,
respectively, which were significantly lower than values of
90.3% and 88.2%, respectively, when the LNR was < 0.20
(p 0.002). The 5-year LRFS for pN2 patients with a LNR
of 0.01-0.20, 0.21 - 0.65, and > 0.65, were 80.0%, 82.1%,
and 44.6%, respectively (p<0.001). Among pN3 patients,
the LNR had no impact the prognosis, but the LRFS was
lower, the 5-year LRFS was 66.7%, 59.2%, and 66.2% for
patients with a LNR of 0.01-0.20, 0.21 - 0.65, and > 0.65,
respectively (p=0.508). The LNR was a prognosis factor
with respect to OS based on pN stage.
Discussion
Although significant progress has been made in under-
standing molecular biomarkers of breast cancer, axillary
lymph node status remains one of the fundamentalprognostic factors that guides the decision for post-
mastectomy radiation therapy [4,5]. Presently, the tumor,
regional lymph node, metastasis (TNM) staging system,
established by the AJCC, is accepted and utilized world-
wide. In this system, the pN staging of axillary lymph
nodes is based on the absolute number of lymph
nodes. Although easy to use, the accuracy of the ap-
proach may be affected by the number of removed
axillary lymph nodes, and thus may be subject to un-
intended variability. In the present study, we explored
the prognostic value of LNR in stage II-III node-
positive breast cancer patients without radiotherapy after
mastectomy, and demonstrated that the LNR can better
predict tumor recurrence and mortality.
The 82b and 82c randomized trials of radiotherapy
conducted by the Danish Breast Cancer Cooperative
Group provided evidence that postoperative adjuvant
radiotherapy has therapeutic value in axillary lymph
node-positive breast cancer; however, the median num-
ber lymph nodes removed was 7, suggesting that adju-
vant therapy used at that time appears insufficient [10].
Nagao et al. [11] showed that the LRFS rate was 8.7%
with radiotherapy and 7.3% without radiotherapy after
mastectomy in lymph node-positive nodes patients, with
Figure 2 Kaplan-Meier cumulative survival curves for different lymph node ratio according to different pN stage. (A, C, E) Locoregional
recurrence-free survival (LRFS) and (B, D, F) overall survival for (A, B) pN1, and (C, D) pN2, and (E, F) pN3.
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study by Gentilini et al. [12] in which patients received no
radiotherapy after mastectomy plus total axillary clearance
(I/II/III region) where the median number of lymph nodes
removed was 23, with the 5-year LRFS rates were 3.0%,
8.1%, and 9.9% for N0, N1 and ≥ N2 stage disease,respectively. These studies suggest that sufficient clearance
of lymph nodes is helpful to reduce locoregional recur-
rence, and thereby affects the decision to administer adju-
vant radiotherapy.
Physician differences and experience can affect the
accuracy of pN staging. Due to variations in the clearance
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findings, the accuracy of pN staging can be compromised.
Furthermore, the optimal number of the axillary lymph
nodes that need to be removed remains controversial
[13,14]. However, Fisher et al. [7] demonstrated that use
of the LNR may minimize the difference in prognosis seen
among hospitals due to different degrees of lymph node
clearance. Several studies have shown that use of the
LNR may change pN staging based on the AJCC
system, and should be considered in addition to
TNM staging in order to provide better guidance
regarding adjuvant therapy [7,9,15-19]. Our study
suggests that the LNR is an independent prognostic
factor of LRFS and OS, and pN staging lost signifi-
cance when LNR was included in the multivariate
analysis. This suggests that LNR has better prognostic
value than pN staging.
Locoregional recurrence is a determinant in the selection
of adjuvant radiotherapy after mastectomy. The St. Gallen
Breast Cancer Conference in 1998 recommended postoper-
ative radiotherapy when the expected LRFS rate was > 20%
[20]. In recent years, research has been concentrated on the
effect of LNR on OS in patients with breast cancer [15-17],
and the studies on LRFS have been mainly conducted in
patients with 1–3 metastatic lymph nodes (pN1) [7,8]. Our
study suggests that LNR is superior to pN staging as a
predictor of LRFS in patients with breast cancer. We
performed subgroup analysis of the prognostic value of
LNR according to different pN stages, and for pN1 patients
the 5-year and 10-year locoregional recurrence rates (LRR)
were 20% and 25.2%, and the LRR was above 20% in
stage pN2 and pN3 patients across all LNR groups.
The value of adjuvant radiotherapy in 1–3 metastatic
lymph nodes is still controversial. Therefore, we
recommend that LNR should be employed as one of the
indications for adjuvant radiotherapy after mastectomy
(i.e., radiation therapy should be considered if the
LNR is > 0.20), instead of a treatment decision based
only on pN stage.
Our study does have several limitations. First, the
conclusions are based on a single center retrospective
study and may not be generalizable to other popula-
tions. However, an increasing amount of data now
supports the prognostic value of LNR in breast
cancer, e.g., the International Nodal Ratio Working
Group is currently undertaking research to establish
the prognostic significance of LNR in breast cancer
[19]. Second, there is no consensus on standard cutoff
points for LNR [7,9,18,19]. The LNR cutoff points
used in this study were based on the report by Vinh-
Hung et al., which has been validated in studies in
other countries [15-17]. Our study suggests that the
cutoff points for the LNR used by Vinh-Hung et al.
are applicable to Chinese women with breast cancer,but a larger sample size is needed to confirm the
results. Third, the prognostic value of Ki-67 was not
analyzed due to missing data, and most of the
patients did not received trastuzumab therapy.
Conclusions
In summary, our study demonstrated that LNR is a
better prognostic predictor than pN stage in patients
with axillary lymph node-positive breast cancer after
mastectomy, and should be used as one of the indications
for adjuvant radiation therapy . Further prospective
studies are necessary to assess the impact of LNR on
prognosis, and to define the usefulness of postoperative
radiotherapy.
Abbreviations
LNR: Lymph node ratio; ER: Estrogen receptor; PR: Progesterone receptor;
Her-2: Human epithelial growth factor receptor family 2; LRFS: Locoregional
recurrence-free survival; OS: Overall survival; CMF: Cyclophosphamide,
methotrexate, and 5-fluorouracil; AJCC: American Joint Committee on
Cancer; TNM: Tumor, regional lymph node, metastasis.
Competing interests
The authors declare they have no competing interests of the article.
Authors’ contributions
SGW,YC, and JYS carried out the data collection and writing of the
manuscript; SGW helped to conceive the study; ZYH contributed to the
design of the study; FYL and QL helped to collect data, HXL participated in
statistical analysis. All authors read and approved the final manuscript.
Acknowledgments
This study was supported by a grant from Sci-Tech Office of Guangdong
Province (No.2008B060 600019) and the Youth Foundation of the First
Affiliated Hospital of Xiamen University (No. XYY2012005).
Author details
1Xiamen Cancer Center, Department of Radiation Oncology, the First
Affiliated Hospital of Xiamen University, Xiamen 361003, People’s Republic of
China. 2State Key Laboratory of Oncology in Southern China, Sun Yat-Sen
University Cancer Center, Guangzhou 510060, People’s Republic of China.
3Department of Radiation Oncology, Sun Yat-Sen University Cancer Center,
Guangzhou 510060, People’s Republic of China.
Received: 19 November 2012 Accepted: 8 May 2013
Published: 14 May 2013
References
1. Overgaard M, Hansen PS, Overgaard J, et al: Postoperative radiotherapy in
high-risk premenopausal women with breast cancer who receive
adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b
Trial. N Engl J Med 1997, 337:949–955.
2. Overgaard M, Jensen MB, Overgaard J, et al: Postoperative radiotherapy in
high-risk postmenopausal breast-cancer patients given adjuvant
tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c
randomised trial. Lancet 1999, 353:1641–1648.
3. Ragaz J, Olivotto IA, Spinelli JJ, et al: Locoregional radiation therapy in
patients with high-risk breast cancer receiving adjuvant chemotherapy:
20-year results of the British Columbia randomized trial. J Natl Canc Inst
2005, 97:116–126.
4. Beenken SW, Urist MM, Zhang Y, et al: Axillary lymph node status, but not
tumor size, predicts locoregional recurrence and overall survival after
mastectomy for breast cancer. Ann Surg 2003, 237:732–738.
5. Singletary SE, Allred C, Ashley P, et al: Revision of the American Joint
Committee on Cancer staging system for breast cancer. J Clin Oncol 2002,
20:3628–3636.
Wu et al. Radiation Oncology 2013, 8:119 Page 8 of 8
http://www.ro-journal.com/content/8/1/1196. Veronesi U, Zurrida S, Viale G, Rethinking TNM, et al: A breast cancer
classification to guide to treatment and facilitate research. Breast J 2009,
15:291–295.
7. Truong PT, Woodward WA, Thames HD, et al: The ratio of positive to
excised nodes identifies high-risk subsets and reduces inter-institutional
differences in locoregional recurrence risk estimates in breast cancer
patients with 1–3 positive nodes: an analysis of prospective data from
British Columbia and the M. D. Anderson Cancer Center. Int J Radiat
Oncol Biol Phys 2007, 68:59–65.
8. Han TJ, Kang EY, Jeon W, et al: The prognostic value of the nodal ratio in
N1 breast cancer. Radiat Oncol 2011, 6:131.
9. Vinh-Hung V, Verkooijen HM, Fioretta G, et al: Lymph node ratio as an
alternative to pN staging in node-positive breast cancer. J Clin Oncol
2009, 27:1062–1068.
10. Overgaard M, Nielsen HM, Overgaard J: Is the benefit of postmastectomy
irradiation limited to patients with four or more positive nodes, as
recommended in international consensus reports? A subgroup analysis
of the DBCG 82 b&c randomized trials. Radiother Oncol 2007, 82:247–253.
11. Nagao T, Kinoshita T, Tamura N, et al: Locoregional recurrence risk factors
in breast cancer patients with positive axillary lymph nodes and the
impact of postmastectomy radiotherapy. Int J Clin Oncol 2013, 18:54–61.
12. Gentilini O, Botteri E, Rotmensz N, et al: Is avoiding post-mastectomy
radiotherapy justified for patients with four or more involved axillary
nodes and endocrine-responsive tumours? Lessons from a series in a
single institution. Ann Oncol 2007, 18:1342–1347.
13. Steering Committee on Clinical Practice Guidelines for the Care and
Treatment of Breast Cancer: Clinical practice guidelines for the care and
treatment of breast cancer. CMAJ 1998, 158(Suppl 3):S1–S83.
14. Fisher B, Wolmark N, Bauer M, et al: The accuracy of clinical nodal staging
and of limited axillary dissection as a determinant of histologic nodal
status in carcinoma of the breast. Surg Gynecol Obstet 1981, 152:765–772.
15. Danko ME, Bennett KM, Zhai J, et al: Improved staging in node-positive
breast cancer patients using lymph node ratio: results in 1,788 patients
with long-term follow-up. J Am Coll Surg 2010, 210:797–805.
16. Chagpar AB, Camp RL, Rimm DL: Lymph node ratio should be considered
for incorporation into staging for breast cancer. Ann Surg Oncol 2011,
18:3143–3148.
17. Ahn SH, Kim HJ, Lee JW, et al: Lymph node ratio and pN staging in
patients with node-positive breast cancer: a report from the Korean
breast cancer society. Breast Canc Res Treat 2011, 130:507–515.
18. Castrucci W, Lannin D, Haffty BG, et al: Using nodal ratios to predict risk of
regional recurrences in patients treated with breast conservation therapy
with 4 or more positive lymph nodes. ISRN Surg 2011, 2011:874814.
19. Vinh-Hung V, Nguyen NP, Cserni G, et al: Prognostic value of nodal ratios
in node-positive breast cancer: a compiled update. Future Oncol 2009,
5:1585–1603.
20. Goldhirsch A, Glick JH, Gelber RD, et al: Meeting highlights: International
Consensus Panel on the Treatment of Primary Breast Cancer. J Natl Canc
Inst 1998, 90:1601–1608.
doi:10.1186/1748-717X-8-119
Cite this article as: Wu et al.: Using the lymph nodal ratio to predict the
risk of locoregional recurrence in lymph node-positive breast cancer
patients treated with mastectomy without radiation therapy. Radiation
Oncology 2013 8:119.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
